drugset

drugset / Trial / NCT00793819

A Study of Silodosin 8 mg Daily for the Treatment of Nocturia in Men With Benign Prostatic Hyperplasia

NCT00793819 ↗

Phase 2 Completed 215 enrolled Watson Pharmaceuticals

RandomizedParallel-groupDouble-blindTreatment

Summary

Silodosin is compared to placebo to determine if it is safe and effective for the treatment of nighttime urination (nocturia) in men with BPH

Timeline

Start: 2009-01
Primary completion: 2009-10
Completion: 2009-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Silodosin	Unknown	8 mg	—

Indications